Antisoma is a biotechnology company specialising in the development of novel drugs for the treatment of cancer.
Antisoma has a diverse portfolio of drugs in development / pipeline
The Company was founded in 1988 and its shares are traded on the London Stock Exchange. Antisoma is based at offices in London and Cambridge, MA.
Antisoma Research Limited
566 Chiswick High Road
Tel: +44 (0) 20 3249 2100
Fax: +44 (0) 20 3249 2101
AS1413 (amonafide L-malate, formerly Xanafide®)
AS1413 is a DNA intercalator that induces apoptotic signalling by blocking TopoII binding to DNA. Unlike classical TopoII inhibitors, a distinctive feature of AS1413 is its ability to evade PgP and related transporters responsible for multi-drug resistance. AS1413 is currently in phase III development in secondary AML.
Secondary AML (acute myeloid leukaemia)
AML is divided into two major categories, de-novo and secondary. AML is classified as secondary AML if it occurs as a result of a prior haematological disease or treatment with chemotherapy or radiation therapy or a combination of the two causes. In a phase II trial, treatment with AS1413 plus cytarabine resulted in a complete response rate of 38.6%, with an additional 3.4% showing CRi (complete response without recovery of blood cell count). This compares with CR rates of around 25% seen with standard treatment in similar AML patients enrolled in two large American studies. AS1413 is now in a phase III registration trial called ACCEDE. The ACCEDE trial compares AS1413 plus cytarabine with daunorubicin plus cytarabine in 450 patients
AS1413 is distinct from daunorubicin and etoposide, poster presentation at AACR, Washington 2010
Pgp impacts on CR rates in AML, poster presentation at ASCO, Chicago 2010
AS1411 has shown activity against a wide range of solid and blood cancer cell lines in preclinical experiments and could therefore have potential against a variety of human cancers. Clinical development is focused on acute myeloid leukaemia (AML).
AS1411 is an aptamer. This is a type of drug based on a short piece of DNA or RNA. However, unlike some other drugs based on these chemicals, aptamers work as conventional drugs, binding to a protein target by virtue of a fit with its three-dimensional structure. The term aptamer is derived from the Greek ‘aptos’ (to fit).
AS1411 has a structure that allows it to bind specifically to a protein called nucleolin, which is found on the surface of many cancer cells. Once bound, the AS1411 aptamer is taken into the cancer cell, where it causes death by apoptosis (programmed cell death).
A previous phase I trial of AS1411 in 30 patients with various advanced cancers reported no serious adverse events related to treatment and promising signs of anti-cancer activity were seen.
AS1411 novel combinations and microarray, poster presentation at AACR, Washington 2010
Long-term outcomes of patients responding to AS1411 regimen, poster presentation at ASCO, Chicago 2010
ATTRACT-1 phase III trial of ASA404 halted following interim analysis
29 March 2010, London, UK, and Cambridge, MA: www.antisoma.com/asm/media/press/pr2010/2010-03-29/
Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that the planned interim analysis of data from the ATTRACT-1 phase III trial of ASA404 in previously untreated non-small cell lung cancer (NSCLC) has shown that continuation of the trial would be futile, as there is little or no prospect of demonstrating a survival benefit with ASA404 in this setting. The ATTRACT-1 trial will therefore be halted.
Press releases 2010
06/03/2010 Antisoma's AS1413 gains FDA Fast Track status for treatment of secondary acute myeloid leukaemia
06/04/2010 Antisoma to present at 9th Annual Needham Life Sciences Conference and 4th Annual Jefferies Healthcare Conference in New York
06/05/2010 Antisoma announces presentation at ASCO of new data supporting AS1413 and AS1411
06/14/2010 Antisoma announces AS1413 and AS1411 presentations at EHA
Annual Report 2009
Antisoma is looking for worldwide partners for the following products:
AS1413 A novel DNA intercalator in phase III for secondary AML
AS1411 A novel DNA aptamer in phase IIb for relapsed/refractory AML
AS1402 A humanised monoclonal antibody (huHMFG1) which targets the glycoprotein, MUC1, that is overexpressed and aberrantly glycosylated in the majority of epithelial tumors. Phase II data are available
AS1409 A fusion protein combining the anti-tumour cytokine IL-12, with the tumour-targeting antibody BC1. A phase I trial with AS1409 in patients with malignant melanoma and renal cell carcinoma has been completed
PPM1D Inhibitor Programme PPM1D is aberrantly amplified in a range of cancers. Activation results in negative regulation of p53 function and other tumour suppressor pathways. Additional functions include the regulation of the base excision pathways of DNA repair. Programme is at lead optimisation
Dendritic Cell Autoimmune Modulators (DCAM) A novel class of oral agents that target specific populations of dendritic cells to modulate the immune response
06/02, 2010: 5,05 GBp
06/03, 2010: 6,10 GBp ( +20,79%) Board Created @ 5,85 GBp
Do your own DD & trade smart
Antisoma has a Level One American Depositary Receipt (ADR) Program.
This will enable US investors in Antisoma to trade in a dollar-denominated security and is intended as a step towards a full listing of Antisoma's shares on NASDAQ.
Trading symbol: ATSMY
CUSIP number: 03718Q109
Ratio: 1 ADR : 20 Ordinary Antisoma shares
Antisoma has appointed The Bank of New York as the depositary bank for our ADR Program.
For more information please contact the Bank of New York:
Telephone from UK: 001 212 815 3700
Telephone from US: 1 888 269 2377 (1 888 BNY ADRS)